ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GBIO Generation Bio Company

3.17
0.06 (1.93%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Generation Bio Company NASDAQ:GBIO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 1.93% 3.17 1.69 3.28 3.36 3.17 3.28 63,938 05:00:03

Generation Bio to Present at William Blair Biotech Focus Conference

08/07/2021 12:30pm

GlobeNewswire Inc.


Generation Bio (NASDAQ:GBIO)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Generation Bio Charts.

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET.

A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.

For more information, please visit www.generationbio.com.

Contact:

InvestorsMaren KillackeyGeneration Biomkillackey@generationbio.com541-646-2420

MediaAlicia WebbGeneration Bioawebb@generationbio.com847-254-4275

Stephanie SimonTen Bridge Communicationsstephanie@tenbridgecommunications.com617-581-9333

1 Year Generation Bio Chart

1 Year Generation Bio Chart

1 Month Generation Bio Chart

1 Month Generation Bio Chart

Your Recent History

Delayed Upgrade Clock